Immunome Clears FDA IND for IM-1340, a First-in-Class ADC for Solid…

Event summary

Immunome received FDA IND clearance for IM-1340, a first-in-class ADC targeting solid tumors.
IM-1340 combines a proprietary HC74 payload with a transport receptor targeting neuroendocrine, lung, and colorectal cancers.
Phase 1 clinical trial initiation expected in Q4 2026.
Preclinical studies showed anti-tumor activity, including tumor regressions in multiple models.

The big picture

Immunome's IND clearance for IM-1340 underscores the growing focus on ADCs as a key modality in oncology. The company's proprietary HC74 payload and differentiated target selection could position it as a contender in the solid tumor space, where treatment options remain limited. Success in this program would further validate Immunome's ADC platform and its ability to deliver first-in-class therapies.

What we're watching

Clinical Execution: Whether IM-1340 can replicate preclinical anti-tumor activity in human trials.
Pipeline Expansion: The pace at which Immunome advances its broader ADC pipeline.
Market Differentiation: How IM-1340's unique target and payload positioning will impact competitive dynamics.